VEGFB and colorectal cancer: Patients with advanced colorectal cancer receiving combined FOLFOX and bevacizumab have decreased VEGFB-mediated angiogenesis, including reduced myeloid cell-endothelial cell communication through VEGF as identified by scRNA-seq.66